What is SCTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.40B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SCTX?

P/E (TTM) is n/a and 52-week range is $13.50 to $39.60 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SCTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

Where is Scribe Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Alameda, California, US, 17.6M shares outstanding, ISIN US8110331092 when available from company profile and filing metadata.

Scribe Therapeutics Inc

$SCTX

Health Care · Biotechnology

Run Scenarios

$21.17

+10.09%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Scribe Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Alameda, California. The company went IPO on 2026-07-24. Scribe Therapeutics, Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. The company focuses on cardiovascular and metabolic (CVM) diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease (ASCVD). The firm's lead product candidate, STX-1150, is an epigenetic silencing therapy that is based on its ELXR technology and is designed to durably lower LDL-C for years to decades by repressing the expression of PCSK9, a genetically and clinically validated target. STX-1150 is designed to achieve long-lasting therapeutic benefit without permanently altering the underlying DNA sequence. Its pipeline also includes STX-1200 and STX-1400, target two additional lipid drivers of ASCVD, elevated Lp(a) and severely high triglycerides, by editing the LPA and APOC3 genes, respectively.

Website

www.scribetx.com

IPO

2026-07-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)